申请人:ASKA Pharmaceutical Co., Ltd.
公开号:EP1908765A1
公开(公告)日:2008-04-09
This invention provides thienopyrimidine derivatives of the formula,
wherein R1 stands for hydrogen atom, an alkyl group or the like; R2 stands for a hydrogen atom, an alkyl or amino group or the like, R3 stands for an alkyl, alkenyl or alkylthio group or the like or a group Y-X-; or R2 and R3 may together form tetramethylene group; X standing for a direct bond or linking group such as CH2, CH(OH), S, O, NH; Y standing for a substituted or unsubstituted aromatic carbocycylic, aromatic heterocylic, cycloalkyl or saturated heterocyclic group or the like; Z stands for S or O, and n is 0 or an integer of 1 to 4,
or salts thereof, which exhibit an inhibitory effect on PDE9, and are therefore useful for prevention or treatment of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria associated with prostatic hyperplasia, urolithiasis, Alzheimer's disease, chronic obstructive pulmonary disease, myocardial infarction, thrombosis, diabetes and the like.
本发明提供了式中的
噻吩嘧啶衍
生物、
其中 R1 代表氢原子、烷基或类似基团;R2 代表氢原子、烷基或
氨基或类似基团;R3 代表烷基、烯基或烷
硫基或类似基团或基团 Y-X-;或 R2 和 R3 可共同形成四亚甲基;X 代表直接键或连接基团,如
CH2、CH(OH)、S、O、NH;Y 代表取代或未取代的芳香碳环、芳香杂环、环烷基或饱和杂环基团或类似基团;Z 代表 S 或 O,n 为 0 或 1 至 4 的整数、
或其盐类,对 PDE9 具有抑制作用,因此可用于预防或治疗膀胱过度活动综合征、花粉尿、尿失禁、前列腺增生相关排尿困难、尿路结石、老年痴呆症、慢性阻塞性肺病、心肌梗塞、血栓形成、糖尿病等。